{"DataElement":{"publicId":"4449956","version":"1","preferredName":"Therapy Complementary and Alternative Medicine Administered Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether nontraditional therapeutic agents/procedures were administered for treatment to alter a disease process (e.g., herbal preparation, vitamin, massage, magnets).","longName":"TX_ALT_MD_ADM_CD_IN","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2013291","version":"4","preferredName":"Therapy Complementary and Alternative Medicine Administered","preferredDefinition":"related to the action of non-traditional therapeutic agents or procedures added to or substituted for treatment to alter a disease process (e.g., herbal preparations, vitamins, massage, magnets).","longName":"TX_COM_ALT_MED_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2416951","version":"1","preferredName":"Therapy","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"02DBEE3F-243E-103A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-12","modifiedBy":"ONEDATA","dateModified":"2005-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2469205","version":"1","preferredName":"CAM Administered","preferredDefinition":"Practices not generally recognized by the medical community as standard or conventional medical approaches and used to replace, enhance or complement standard treatments. Complementary medicine includes dietary supplements, megadose vitamins, herbal preparations, special teas, acupuncture, massage therapy, magnet therapy, spiritual healing, and meditation.:Given.","longName":"C15178:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complementary and Alternative Medicine","conceptCode":"C15178","definition":"A group of diverse medical and health care systems, practices, and products that are not presently considered to be part of conventional medicine. Complementary medicine as being used together with conventional medicine, whereas alternative medicine is used in place of conventional medicine. The National Center for Complementary and Alternative Medicine (NCCAM) groups CAM practices into four domains, recognizing there can be some overlap: mind-body medicine; biologically based practices, manipulative and body-based practices, and energy medicine. In addition, NCCAM studies CAM whole medical systems, which cut across all domains.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10B16D39-C5E7-2BD6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-05","endDate":null,"createdBy":"PWEST","dateCreated":"2006-04-05","modifiedBy":"ONEDATA","dateModified":"2006-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10B125EA-EE7D-1C54-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-05","endDate":null,"createdBy":"PWEST","dateCreated":"2006-04-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"updated for ISO compliance for use on new protocol","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"3303197","version":"1","longName":"Phase 1/Pilot Consortium","context":"COG"}]},{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"10000494","version":"1","longName":"Prior Treatments","context":"Theradex"},{"publicId":"3876426","version":"1","longName":"Physical & Concomitant Requirements","context":"Theradex"}]},{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"10000083","version":"1","longName":"Physical & Concomitant Requirements","context":"Theradex"},{"publicId":"3876424","version":"1","longName":"Prior Treatments","context":"Theradex"}]},{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"},{"name":"ABTC","type":"USED_BY","context":"ABTC"},{"name":"PBTC","type":"USED_BY","context":"PBTC"}],"ReferenceDocuments":[{"name":"Theradex - 12","type":"Alternate Question Text","description":"Has patient received herbal therapy intended as anticancer therapy within 1 week prior to randomization?","url":null,"context":"Theradex"},{"name":"Is patient taking concurrent","type":"Preferred Question Text","description":"Is patient taking concurrent herbal supplements (including, but not limited to, St. John's wort, kava, ephedra [ma huang], ginkgo biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng) while on study?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Has patient used natural herbal products or other complementary alternative medications (CAM) or \"folk remedies\" within one week of starting study and will continue using them concurrently while participating on this study?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Is patient taking concurrent herbal supplements (including, but not limited to, cannabis,  St. John's wort, kava, ephedra [ma huang], ginkgo biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng) while on study?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Is patient currently using natural herbal products or other complementary alternative medications (CAM) or folk remedies?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Is patient receiving vitamin E supplementation?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Has patient received herbal therapy, intended as anticancer therapy, within 1 week prior to cycle 1, day 1?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Is patient using (currently) natural herbal products or other folk remedies?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"If patient has received prior herbal therapy was last dose more than 1 week prior to cycle 1, day 1?","url":null,"context":"Theradex"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Has patient received herbal preparations during the indicated time period","url":null,"context":"COG"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Is patient currently taking natural herb products or other complementary alternative medications or if used previously, patients must have at least 1-week washout and must stop using them while participating in this study?","url":null,"context":"Theradex"},{"name":"ABTC - 1602 Question","type":"Alternate Question Text","description":"Has the patient received herbal or non-traditional medications while receiving AMG 232 therapy within 30 days prior to start of treatment?","url":null,"context":"ABTC"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Is patient receiving, or is intended to receive ongoing treatment with: herbal remedies (e.g., St. John's wort), or strong inhibitors or inducers of P-glycoprotein (Pgp) or breast cancer resistance protein 1 (Bcrp1)?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"If patient has taken any herbal medicines (e.g., St. John's wort), vitamins, and supplements within the 30 days prior to receiving the first dose of AMG 232 has continued use, if applicable, been reviewed by the Principal Investigator?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Is patient taking herbal preparations, including but not limited to: St. John's wort, kava, ephedra (ma hung), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto and ginseng within 7 days prior to first dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Is patient taking herbal preparations, including but not limited to: St. John's wort, kava, ephedra (ma hung), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto and ginseng within 7 days prior to first dose of study treatment or while on study?","url":null,"context":"Theradex"},{"name":"PBTC_Text1","type":"Alternate Question Text","description":"Has the patient within the last 7 days received any herbal medications including  but not limited to cannabis products, Kava, epedra (ma huang), gingko bilboa, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto and ginseng?","url":null,"context":"PBTC"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Is patient taking herbal medications/preparations (except for vitamins)?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Is patient taking any herbal medications/preparations (except for vitamins)?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"If patient has received herbal therapy intended as anticancer therapy, was it discontinued greater than or equal to 1 week prior to initiation of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Has patient received herbal therapy intended as anticancer therapy less than 1 week prior to initiation of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Is patient currently receiving (and is unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Is patient taking herbal medications/preparations (except for vitamins) or anti-arrhythmic therapy other than beta blockers or digoxin?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Will patient receive herbal medications/preparations (except for vitamins) while on copanlisib treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"If patient has taken any herbal medicines (e.g., St. John's wort), vitamins, and supplements within the 30 days prior to receiving the first dose of KRT-232 (AMG 232) or venetoclax has continued use, if applicable, been reviewed by the Principal Investigator?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Is patient taking herbal medications, including but are not limited to: St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Is patient taking herbal medications/preparations?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Has patient's medication list such as herbal medicines (e.g., St. John's wort), vitamins, and supplements, been reviewed before starting first dose of KRT-232 (AMG 232)?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Is patient receiving herbal remedies with immunostimulating properties (e.g., mistletoe extract) or known to potentially interfere with major organ function (e.g. hypericin) at the time of enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Is the patient considering the use of a new over the counter medicine or herbal product?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Is patient currently using or has anticipated need for alternative, holistic, naturopathic, or botanical formulations used for the purpose of cancer treatment?","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008C4FAD-BEAB-835A-E050-BB89AD432DFD","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2023-10-17","changeDescription":"12/5/16 tt, added CSIs.9591_Theradex_08.13.14_ghd 3/18/2020 fixed Ref Docs with special characters DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}